EMI (Encore Medical) PB Ratio: (As of Jun. 25, 2026)


What is Encore Medical PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Encore Medical's share price is $0.00. Encore Medical's Book Value per Share for the quarter that ended in Dec. 2025 was $-0.17. Hence, Encore Medical's PB Ratio of today is .

The historical rank and industry rank for Encore Medical's PB Ratio or its related term are showing as below:

EMI's PB Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.045
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Encore Medical  (AMEX:EMI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Encore Medical PB Ratio Related Terms


Encore Medical PB Ratio Historical Data

* Premium members only.

The historical data trend for Encore Medical's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical PB Ratio Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
PB Ratio Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

EMI vs : PB Ratio Comparison

For the Medical Instruments & Supplies subindustry, Encore Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Encore Medical PB Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's PB Ratio distribution charts can be found below:

* The bar in red indicates where Encore Medical's PB Ratio falls into.



Encore Medical PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Encore Medical's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.00/-0.172
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).